Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1224366 | 1.00 | MEN1 (0.45) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL1224364 | 1.00 | MEN1 (0.45) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL570033 | 0.88 | MEN1 (0.50) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL28118520 | 0.84 | SYK (0.36) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL13960156 | 0.83 | MEN1 (0.46) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL5352030 | 0.83 | MEN1 (0.46) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL16379307 | 0.83 | MEN1 (0.46) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL1222350 | 0.83 | TDP1 (0.49) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL1222348 | 0.83 | TDP1 (0.49) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL2369074 | 0.83 | MEN1 (0.46) | MEN1GAAKMT2ATDP1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2766373-B1 | SILA ANALOGS OF OXAZOLIDINONE DERIVATIVES AND SYNTHESIS THEREOF | COUNCIL SCIENT IND RES (IN) | 2016-08-17 | — | — | EP | claimed |
| US-9233989-B2 | Sila analogs of oxazolidinone derivatives and synthesis thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-01-12 | — | — | US | claimed |
| CN-103467310-B | Separation and purification method for (S)-1-amino-3-chloro-2-propanol hydrochloride | CHONGQING HUIJIAN BIOTECH CO LTD | 2015-05-27 | — | — | CN | claimed |
| US-20140296133-A1 | SILA ANALOGS OF OXAZOLIDINONE DERIVATIVES AND SYNTHESIS THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-10-02 | — | — | US | claimed |
| EP-2766373-A1 | SILA ANALOGS OF OXAZOLIDINONE DERIVATIVES AND SYNTHESIS THEREOF | Council of Scientific & Industrial Research (IN) | 2014-08-20 | — | — | EP | claimed |
| WO-2013054275-A1 | SILA ANALOGS OF OXAZOLIDINONE DERIVATIVES AND SYNTHESIS THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-04-18 | — | — | WO | claimed |
| US-20260007613-A1 | LONG-ACTING LOW-TOXICITY NOVEL CATIONIC LIPID COMPOUNDS AND COMPOSITION THEREOF | BEIJING YOUCAREKECHUANG PHARMACEUTICAL TECH CO LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| EP-4588910-A1 | LONG-ACTING LOW-TOXICITY NOVEL CATIONIC LIPID COMPOUNDS AND COMPOSITION THEREOF | Beijing Youcarekechuang Pharmaceutical Technology Co., Ltd. (CN) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024200838-A1 | NEW ODILORHABDINS ANALOGUES AS ANTIBIOTICS AGAINST MULTI-RESISTANT BACTERIA | NOSOPHARM (FR) | 2024-10-03 | — | — | WO | disclosed |
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| WO-2023206874-A1 | SACUBITRIL INTERMEDIATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 凯特立斯（深圳）科技有限公司 | 2023-11-02 | — | — | WO | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | RENSLO ADAM (US) | 2005-09-01 | — | — | US | disclosed |
| US-6833453-B2 | As an example, manufacturing a 5-(tert-butylcarbamoyl)-amino-methyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or a 3-amino-1-halopropanol | PHARMACIA & UPJOHN COMPANY | 2004-12-21 | — | — | US | disclosed |
| WO-2004089943-A1 | ANTIMICROBIAL [3.1.0] BICYCLOHEXYLPHENYL-OXAZOLIDINONE DERIVATIVES AND ANALOGUES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040143131-A1 | in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| EP-1328509-A1 | METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS | Pharmacia & Upjohn Company (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20020086900-A1 | Methods of producing oxazolidinone compounds | PERRAULT WILLIAM R (US) | 2002-07-04 | — | — | US | disclosed |
| WO-2002032857-A1 | METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | MEN1 182/4885GAA 592/4885KMT2A 3722/4885 |
| US-20040143131-A1 | in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates | TET1, NAT10, TET3 | MEN1 3212/4885GAA 1801/4885KMT2A 1744/4885 |
| US-20140296133-A1 | SILA ANALOGS OF OXAZOLIDINONE DERIVATIVES AND SYNTHESIS THEREOF | STS, F2, TFPI | MEN1 2561/4885GAA 2110/4885KMT2A 883/4885 |
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | OXA1L, CYP51A1, CYP2C19 | MEN1 3159/4885GAA 2035/4885KMT2A 4793/4885 |
| US-20020086900-A1 | Methods of producing oxazolidinone compounds | TET3, TET1, AZI2 | MEN1 2766/4885GAA 1234/4885KMT2A 2048/4885 |
| US-20260007613-A1 | LONG-ACTING LOW-TOXICITY NOVEL CATIONIC LIPID COMPOUNDS AND COMPOSITION THEREOF | NPC1L1, VEGFA, LDLR | MEN1 4533/4885GAA 1850/4885KMT2A 4050/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | MEN1 182/4885GAA 592/4885KMT2A 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.